Study Phase 3

A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.

Trial Information

Generic NameLevofloxacinProduct NameLEVAQUIN®Therapeutic AreaUrinary Tract, Sexual Organs, and Pregnancy ConditionsEnrollment1109% Female60.9%% White68.5%
Product ClassQuinolones - 3rd gen.Sponsor Protocol NumberCAPSS-349Data PartnerJohnson & JohnsonCondition StudiedPyelonephritis, Urinary Tract InfectionsMean/Median Age (Years)54.2

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.